Drug Combination Details
General Information of the Combination (ID: C69848) | |||||
---|---|---|---|---|---|
Name | Calycosin NP Info | + | Doxorubicin Drug Info | ||
Structure |
![]() |
+ |
![]() |
||
Disease |
Healthy individual
[ICD-11: N.A.]
|
Investigative | [1] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Reversing Drug Resistance by This Combination | ||||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [1] | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | SIRT1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | H9c2(2-1) | CVCL_0286 | Healthy | Rattus norvegicus | ||
In-vivo Model | Male Kunming mice (8- 10 weeks old; body weight: 22 +/- 2 g) were used to construct a short-term model of cardiomyopathy. | |||||
Experimental
Result(s) |
Calycosin ameliorates doxorubicin-induced cardiotoxicity by suppressing oxidative stress and inflammation via the sirtuin 1-NOD-like receptor protein 3 pathway. |
